<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257243</url>
  </required_header>
  <id_info>
    <org_study_id>OGPGEMS0110</org_study_id>
    <nct_id>NCT01257243</nct_id>
  </id_info>
  <brief_title>Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment</brief_title>
  <official_title>Multicentric, Randomized, Open-label Trial to Evaluate the Superiority of Fixed Dose Combination of Oxomemazine, Guaifenesin and Potassium Iodate to Guaifenesin Monotherapy in Acute Cough Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine,
      guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN

        -  Open-label, superiority, prospective, parallel group, intent to treat trial

        -  Experiment duration: 7 days

        -  3 visits (days 1, 2 and 7)

        -  Reduction cough symptoms

        -  Adverse events evaluation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2012</start_date>
  <completion_date type="Actual">October 25, 2013</completion_date>
  <primary_completion_date type="Actual">September 30, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction/improvement of cough symptoms</measure>
    <time_frame>DAY 7</time_frame>
    <description>The reduction of cough symptoms will be evaluated by comparative score index basal and final score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>DAY 7</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>DRUG 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Syrup of oxomemazine, guaifenesin and potassium iodate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DRUG 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Syrup of guaifenesin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syrup of oxomemazine, guaifenesin and potassium iodate</intervention_name>
    <description>5ml each 4 hours</description>
    <arm_group_label>DRUG 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syrup of guaifenesin</intervention_name>
    <description>5ml each 4 hours</description>
    <arm_group_label>DRUG 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with productive cough as result an acute URTI (i.e., cold or flu) or allergic
             cough in the last 10 day.

          3. Cough score superior to 3.

        Exclusion Criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation.

          3. Fever above 38º C.

          4. Patients with bacterial infections of the upper respiratory tract.

          5. Any pathology or past medical condition that can interfere with this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Pinho, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beneficência Nipo Brasileira de São Paulo - Hospital Nipo Brasileiro</name>
      <address>
        <city>São Paulo</city>
        <zip>02189-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cough</keyword>
  <keyword>symptoms</keyword>
  <keyword>cold</keyword>
  <keyword>flu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Potassium iodate</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

